EANS-News: Swiss authorities grant product approval for IXIARO®

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: Intercell's vaccine to help prevent Japanese Encephalitis now
available in Switzerland

Vienna (Austria), July 13, 2010 (euro adhoc) - Intercell AG (VSE: ICLL)
announces that Swissmedic has approved IXIARO®, its vaccine against Japanese
Encephalitis. IXIARO®, which is distributed and marketed by Novartis, is now
available in Switzerland.

The decision by the Swiss authorities represents another important milestone for
the licensure process initiated for selected attractive market segments.
Intercell's vaccine, which helps to prevent Japanese Encephalitis, has already
been approved and launched in the USA, Europe, Canada and Australia.

"The Swissmedic approval is great news and another important step in the
product's global reach", states Thomas Lingelbach, Chief Operating Officer of
Intercell.

IXIARO® is a modern purified, inactivated vaccine for active immunization of
adults against infections caused by the Japanese Encephalitis Virus. IXIARO® is
manufactured at Intercell's proprietary manufacturing facility in Scotland using
tissue culture rather than live organisms.

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print